252 results on '"Rivella, Stefano"'
Search Results
2. Pathogenic Mechanisms in Thalassemia I
- Author
-
Bou-Fakhredin, Rayan, Rivella, Stefano, Cappellini, Maria Domenica, and Taher, Ali T.
- Abstract
Erythropoiesis is the physiological process that results in the production of red blood cells (RBCs). In conditions of pathologically altered erythropoiesis or ineffective erythropoiesis, as in the case of β-thalassemia, the reduced ability of erythrocytes to differentiate, survive and deliver oxygen stimulates a state of stress that leads to the ineffective production of RBCs. We herein describe the main features of erythropoiesis and its regulation in addition to the mechanisms behind ineffective erythropoiesis development in β-thalassemia. Finally, we review the pathophysiology of hypercoagulability and vascular disease development in β-thalassemia and the currently available prevention and treatment modalities.
- Published
- 2023
- Full Text
- View/download PDF
3. Lnp-Targeting Hematopoietic Stem Cells and Lentiviral Gene Transfer to Generate and Rescue a Novel Mouse Model of Lethal Alpha-Thalassemia
- Author
-
Chappell, Maxwell, Breda, Laura, Jarocha, Danuta Jadwiga, Triebwasser, Michael, Papp, Tyler E, Ghiaccio, Valentina, Fedorky, Megan T, Guerra, Amaliris, Gollomp, Kandace, Abdulmalik, Osheiza Y., Teawtrakul, Nattiya, Glentis, Stavros, Kattamis, Antonis, Parhiz, Hamideh, and Rivella, Stefano
- Published
- 2022
- Full Text
- View/download PDF
4. Lnp-Targeting Hematopoietic Stem Cells and Lentiviral Gene Transfer to Generate and Rescue a Novel Mouse Model of Lethal Alpha-Thalassemia
- Author
-
Chappell, Maxwell, Breda, Laura, Jarocha, Danuta Jadwiga, Triebwasser, Michael, Papp, Tyler E, Ghiaccio, Valentina, Fedorky, Megan T, Guerra, Amaliris, Gollomp, Kandace, Abdulmalik, Osheiza Y., Teawtrakul, Nattiya, Glentis, Stavros, Kattamis, Antonis, Parhiz, Hamideh, and Rivella, Stefano
- Published
- 2022
- Full Text
- View/download PDF
5. Establishment of High Titer Baboon Endogenous Retrovirus Envelope Pseudotyped Lentiviral Vector Production Protocol Focusing on Syncytium Formation and Exfoliation
- Author
-
Noguchi, Kazuhiro, Ikawa, Yasuhiro, Takenaka, Mika, Sakai, Yuta, Fujiki, Toshihiro, Kuroda, Rie, Chappell, Maxwell, Ghiaccio, Valentina, Rivella, Stefano, and Wada, Taizo
- Published
- 2022
- Full Text
- View/download PDF
6. Establishment of High Titer Baboon Endogenous Retrovirus Envelope Pseudotyped Lentiviral Vector Production Protocol Focusing on Syncytium Formation and Exfoliation
- Author
-
Noguchi, Kazuhiro, Ikawa, Yasuhiro, Takenaka, Mika, Sakai, Yuta, Fujiki, Toshihiro, Kuroda, Rie, Chappell, Maxwell, Ghiaccio, Valentina, Rivella, Stefano, and Wada, Taizo
- Published
- 2022
- Full Text
- View/download PDF
7. Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies
- Author
-
Breda, Laura, Ghiaccio, Valentina, Tanaka, Naoto, Jarocha, Danuta, Ikawa, Yasuhiro, Abdulmalik, Osheiza, Dong, Alisa, Casu, Carla, Raabe, Tobias D., Shan, Xiaochuan, Danet-Desnoyers, Gwenn A., Doto, Aoife M., Everett, John, Bushman, Frederic D., Radaelli, Enrico, Assenmacher, Charles A., Tarrant, James C., Hoepp, Natalie, Kurita, Ryo, Nakamura, Yukio, Guzikowski, Virginia, Smith-Whitley, Kim, Kwiatkowski, Janet L., and Rivella, Stefano
- Abstract
Ongoing clinical trials for treatment of beta-globinopathies by gene therapy involve the transfer of the beta-globin gene, which requires integration of three to four copies per genome in most target cells. This high proviral load may increase genome toxicity, potentially limiting the safety of this therapy and relegating its use to total body myeloablation. We hypothesized that introducing an additional hypersensitive site from the locus control region, the complete sequence of the second intron of the beta-globin gene, and the ankyrin insulator may enhance beta-globin expression. We identified a construct, ALS20, that synthesized significantly higher adult hemoglobin levels than those of other constructs currently used in clinical trials. These findings were confirmed in erythroblastic cell lines and in primary cells isolated from sickle cell disease patients. Bone marrow transplantation studies in beta-thalassemia mice revealed that ALS20 was curative at less than one copy per genome. Injection of human CD34+cells transduced with ALS20 led to safe, long-term, and high polyclonal engraftment in xenograft experiments. Successful treatment of beta-globinopathies with ALS20 could potentially be achieved at less than two copies per genome, minimizing the risk of cytotoxic events and lowering the intensity of myeloablation.
- Published
- 2021
- Full Text
- View/download PDF
8. Hematopoietic stem cell gene therapy improves outcomes in a clinically relevant mouse model of Multiple Sulfatase Deficiency
- Author
-
Pham, Vi, Tricoli, Lucas, Hong, Xinying, Wongkittichote, Parith, Castracani, Carlo Castruccio, Guerra, Amaliris, Schlotawa, Lars, Adang, Laura A., Kuhs, Amanda, Cassidy, Margaret M., Kane, Owen, Tsai, Emily, Presa, Maximiliano, Lutz, Cathleen, Rivella, Stefano B., and Ahrens-Nicklas, Rebecca C.
- Abstract
Multiple sulfatase deficiency (MSD) is a severe, lysosomal storage disorder caused by pathogenic variants in the gene SUMF1,encoding the sulfatase modifying factor formylglycine-generating enzyme. Patients with MSD exhibit functional deficiencies in all cellular sulfatases. The inability of sulfatases to break down their substrates leads to progressive and multi-systemic complications in patients, similar to those seen in single-sulfatase disorders such as metachromatic leukodystrophy and mucopolysaccharidoses IIIA. Here, we aimed to determine if hematopoietic stem cell transplant with ex vivo SUMF1lentiviral gene therapy could improve outcomes in a clinically relevant mouse model of MSD. We first tested our approach in MSD patient-derived cells and found that our SUMF1lentiviral vector improved protein expression, sulfatase activities, and glycosaminoglycan accumulation. In vivo, we found that our gene therapy approach rescued biochemical deficits, including sulfatase activity and glycosaminoglycan accumulation, in affected organs of MSD mice treated post-symptom onset. In addition, treated mice demonstrated improved neuroinflammation and neurocognitive function. Together, these findings suggest that SUMF1HSCT-GT can improve both biochemical and functional disease markers in the MSD mouse.
- Published
- 2024
- Full Text
- View/download PDF
9. Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy
- Author
-
Chappell, Maxwell E., Breda, Laura, Tricoli, Lucas, Guerra, Amaliris, Jarocha, Danuta, Castruccio Castracani, Carlo, Papp, Tyler E., Tanaka, Naoto, Hamilton, Nolan, Triebwasser, Michael P., Ghiaccio, Valentina, Fedorky, Megan T., Gollomp, Kandace L., Bochenek, Veronica, Roche, Aoife M., Everett, John K., Cook, Emma J., Bushman, Frederic D., Teawtrakul, Nattiya, Glentis, Stavros, Kattamis, Antonis, Mui, Barbara L., Tam, Ying K., Weissman, Drew, Abdulmalik, Osheiza, Parhiz, Hamideh, and Rivella, Stefano
- Abstract
•Deletion of the α-globin genes induces a lethal phenotype associated with high levels of red blood cells in circulation.•Transduction with a lentiviral vector expressing the human α-globin gene prevents mice from developing the lethal phenotype.
- Published
- 2024
- Full Text
- View/download PDF
10. Carbonyl iron and iron dextran therapies cause adverse effects on bone health in juveniles with chronic kidney disease
- Author
-
Patino, Edwin, Doty, Stephen B., Bhatia, Divya, Meza, Kelly, Zhu, Yuan-Shan, Rivella, Stefano, Choi, Mary E., and Akchurin, Oleh
- Abstract
Anemia is a frequent complication of chronic kidney disease (CKD), related in part to the disruption of iron metabolism. Iron therapy is very common in children with CKD and excess iron has been shown to induce bone loss in non-CKD settings, but the impact of iron on bone health in CKD remains poorly understood. Here, we evaluated the effect of oral and parenteral iron therapy on bone transcriptome, bone histology and morphometry in two mouse models of juvenile CKD (adenine-induced and 5/6-nephrectomy). Both modalities of iron therapy effectively improved anemia in the mice with CKD, and lowered bone Fgf23expression. At the same time, iron therapy suppressed genes implicated in bone formation and resulted in the loss of cortical and trabecular bone in the mice with CKD. Bone resorption was activated in untreated CKD, but iron therapy had no additional effect on this. Furthermore, we assessed the relationship between biomarkers of bone turnover and iron status in a cohort of children with CKD. Children treated with iron had lower levels of circulating biomarkers of bone formation (bone-specific alkaline phosphatase and the amino-terminal propeptide of type 1 procollagen), as well as fewer circulating osteoblast precursors, compared to children not treated with iron. These differences were independent of age, sex, and glomerular filtration rate. Thus, iron therapy adversely affected bone health in juvenile mice with CKD and was associated with low levels of bone formation biomarkers in children with CKD.
- Published
- 2020
- Full Text
- View/download PDF
11. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity
- Author
-
Casu, Carla, Pettinato, Mariateresa, Liu, Alison, Aghajan, Mariam, Lo Presti, Vania, Lidonnici, Maria Rosa, Munoz, Kevin A., O’Hara, Emir, Olivari, Violante, Di Modica, Simona Maria, Booten, Sheri, Guo, Shuling, Neil, Garry, Miari, Reem, Shapir, Nir, Zafir-Lavie, Inbal, Domev, Hagit, Ferrari, Giuliana, Sitara, Despina, Nai, Antonella, and Rivella, Stefano
- Abstract
β-Thalassemia intermedia is a disorder characterized by ineffective erythropoiesis (IE), anemia, splenomegaly, and systemic iron overload. Novel approaches are being explored based on the modulation of pathways that reduce iron absorption (ie, using hepcidin activators like Tmprss6-antisense oligonucleotides [ASOs]) or increase erythropoiesis (by erythropoietin [EPO] administration or modulating the ability of transferrin receptor 2 [Tfr2] to control red blood cell [RBC] synthesis). Targeting Tmprss6 messenger RNA by Tmprss6-ASO was proven to be effective in improving IE and splenomegaly by inducing iron restriction. However, we postulated that combinatorial strategies might be superior to single therapies. Here, we combined Tmprss6-ASO with EPO administration or removal of a single Tfr2 allele in the bone marrow of animals affected by β-thalassemia intermedia (Hbbth3/+). EPO administration alone or removal of a single Tfr2 allele increased hemoglobin levels and RBCs. However, EPO or Tfr2 single-allele deletion alone, respectively, exacerbated or did not improve splenomegaly in β-thalassemic mice. To overcome this issue, we postulated that some level of iron restriction (by targeting Tmprss6) would improve splenomegaly while preserving the beneficial effects on RBC production mediated by EPO or Tfr2 deletion. While administration of Tmprss6-ASO alone improved the anemia, the combination of Tmprss6-ASO + EPO or Tmprss6-ASO + Tfr2 single-allele deletion produced significantly higher hemoglobin levels and reduced splenomegaly. In conclusion, our results clearly indicate that these combinatorial approaches are superior to single treatments in ameliorating IE and anemia in β-thalassemia and could provide guidance to translate some of these approaches into viable therapies.
- Published
- 2020
- Full Text
- View/download PDF
12. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity
- Author
-
Casu, Carla, Pettinato, Mariateresa, Liu, Alison, Aghajan, Mariam, Lo Presti, Vania, Lidonnici, Maria Rosa, Munoz, Kevin A., O'Hara, Emir, Olivari, Violante, Di Modica, Simona Maria, Booten, Sheri, Guo, Shuling, Neil, Garry, Miari, Reem, Shapir, Nir, Zafir-Lavie, Inbal, Domev, Hagit, Ferrari, Giuliana, Sitara, Despina, Nai, Antonella, and Rivella, Stefano
- Abstract
β-Thalassemia intermedia is a disorder characterized by ineffective erythropoiesis (IE), anemia, splenomegaly, and systemic iron overload. Novel approaches are being explored based on the modulation of pathways that reduce iron absorption (ie, using hepcidin activators like Tmprss6-antisense oligonucleotides [ASOs]) or increase erythropoiesis (by erythropoietin [EPO] administration or modulating the ability of transferrin receptor 2 [Tfr2] to control red blood cell [RBC] synthesis). Targeting Tmprss6messenger RNA by Tmprss6-ASO was proven to be effective in improving IE and splenomegaly by inducing iron restriction. However, we postulated that combinatorial strategies might be superior to single therapies. Here, we combined Tmprss6-ASO with EPO administration or removal of a single Tfr2allele in the bone marrow of animals affected by β-thalassemia intermedia (Hbbth3/+). EPO administration alone or removal of a single Tfr2allele increased hemoglobin levels and RBCs. However, EPO or Tfr2single-allele deletion alone, respectively, exacerbated or did not improve splenomegaly in β-thalassemic mice. To overcome this issue, we postulated that some level of iron restriction (by targeting Tmprss6) would improve splenomegaly while preserving the beneficial effects on RBC production mediated by EPO or Tfr2deletion. While administration of Tmprss6-ASO alone improved the anemia, the combination of Tmprss6-ASO + EPO or Tmprss6-ASO + Tfr2single-allele deletion produced significantly higher hemoglobin levels and reduced splenomegaly. In conclusion, our results clearly indicate that these combinatorial approaches are superior to single treatments in ameliorating IE and anemia in β-thalassemia and could provide guidance to translate some of these approaches into viable therapies.
- Published
- 2020
- Full Text
- View/download PDF
13. Heparanase Level and Procoagulant Activity Are Increased in Thalassemia and Attenuated by Janus Kinase 2 Inhibition
- Author
-
Ghoti, Hussam, Ackerman, Shanny, Rivella, Stefano, Casu, Carla, and Nadir, Yona
- Abstract
Patients with thalassemia exhibit an increased risk of thrombotic events that is augmented after splenectomy. Heparanase protein enhances cancer progression, angiogenesis, and inflammation; it also activates the coagulation system through direct interaction with tissue factor (TF). Additionally, erythropoietin, which is elevated in anemic patients, up-regulates heparanase expression via the Janus kinase 2 (JAK-2) pathway. This study aimed was to explore the heparanase profile in thalassemia. Coagulation factors were analyzed via immunostaining, enzyme-linked immunosorbent assay, and heparanase procoagulant activity assay. In spleen specimens of thalassemia major patients, a higher level of heparanase staining was observed compared with control spleens resected after trauma (P < 0.001). Higher heparanase levels, heparanase and TF procoagulant activity, and erythropoietin levels were found in the plasma of 67 thalassemia major patients compared with 29 control subjects. No difference was found in pediatric patients (23 of 67) compared with adults or splenectomized versus nonsplenectomized patients. Higher levels of heparanase, TF, TF pathway inhibitor, and TF pathway inhibitor-2 were observed in liver, spleen, heart, and kidney tissues of thalassemia intermedia mice (Hbbth3/+). These protein levels significantly reduced when mice were treated with the JAK-2 inhibitor ruxolitinib (P < 0.0001). In summary, heparanase levels are elevated in thalassemia, which may contribute to thrombotic phenomena in these patients. Inhibition of heparanase or the JAK-2 pathway may reduce thrombotic risk in thalassemia.
- Published
- 2020
- Full Text
- View/download PDF
14. Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells
- Author
-
Bystrom, Laura M., Bezerra, Daniel P., Hsu, Hsiao-Ting, Zong, Hongliang, Lara-Martínez, Luis A., De Leon, Jeanne P., Emmanuel, Megan, Méry, David, Gardenghi, Sara, Hassane, Duane, Neto, Catherine C., Cunningham-Rundles, Susanna, Becker, Michael W., Rivella, Stefano, and Guzman, Monica L.
- Abstract
Most elderly patients affected with acute myeloid leukemia (AML) will relapse and die of their disease even after achieving complete remission, thus emphasizing the urgent need for new therapeutic approaches with minimum toxicity to normal hematopoietic cells. Cranberry (Vaccinium spp.) extracts have exhibited anticancer and chemopreventive properties that have been mostly attributed to A-type proanthocyanidin (A-PAC) compounds. A-PACs, isolated from a commercially available cranberry extract, were evaluated for their effects on leukemia cell lines, primary AML samples, and normal CD34+ cord blood specimens. Our results indicated potent and specific antileukemia activity in vitro. In addition, the antileukemia activity of A-PACs extended to malignant progenitor and stem cell populations, sparing their normal counterparts. The antileukemia effects of A-PACs were also observed in vivo using patient derived xenografts. Surprisingly, we found that the mechanism of cell death was driven by activation of NF-κB. Overall, our data suggest that A-PACs could be used to improve treatments for AML by targeting leukemia stem cells through a potentially novel pathway.
- Published
- 2019
- Full Text
- View/download PDF
15. Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells
- Author
-
Bystrom, Laura M., Bezerra, Daniel P., Hsu, Hsiao-Ting, Zong, Hongliang, Lara-Martínez, Luis A., De Leon, Jeanne P., Emmanuel, Megan, Méry, David, Gardenghi, Sara, Hassane, Duane, Neto, Catherine C., Cunningham-Rundles, Susanna, Becker, Michael W., Rivella, Stefano, and Guzman, Monica L.
- Abstract
Most elderly patients affected with acute myeloid leukemia (AML) will relapse and die of their disease even after achieving complete remission, thus emphasizing the urgent need for new therapeutic approaches with minimum toxicity to normal hematopoietic cells. Cranberry (Vacciniumspp.) extracts have exhibited anticancer and chemopreventive properties that have been mostly attributed to A-type proanthocyanidin (A-PAC) compounds. A-PACs, isolated from a commercially available cranberry extract, were evaluated for their effects on leukemia cell lines, primary AML samples, and normal CD34+cord blood specimens. Our results indicated potent and specific antileukemia activity in vitro. In addition, the antileukemia activity of A-PACs extended to malignant progenitor and stem cell populations, sparing their normal counterparts. The antileukemia effects of A-PACs were also observed in vivo using patient derived xenografts. Surprisingly, we found that the mechanism of cell death was driven by activation of NF-κB. Overall, our data suggest that A-PACs could be used to improve treatments for AML by targeting leukemia stem cells through a potentially novel pathway.
- Published
- 2019
- Full Text
- View/download PDF
16. Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis
- Author
-
Parrow, Nermi L., Li, Yihang, Feola, Maria, Guerra, Amaliris, Casu, Carla, Prasad, Princy, Mammen, Luke, Ali, Faris, Vaicikauskas, Edvinas, Rivella, Stefano, Ginzburg, Yelena Z., and Fleming, Robert E.
- Abstract
Transferrin, the major plasma iron-binding molecule, interacts with cell-surface receptors to deliver iron, modulates hepcidin expression, and regulates erythropoiesis. Transferrin binds and releases iron via either or both of 2 homologous lobes (N and C). To test the hypothesis that the specificity of iron occupancy in the N vs C lobe influences transferrin function, we generated mice with mutations to abrogate iron binding in either lobe (TfN-bl or TfC-bl). Mice homozygous for either mutation had hepatocellular iron loading and decreased liver hepcidin expression (relative to iron concentration), although to different magnitudes. Both mouse models demonstrated some aspects of iron-restricted erythropoiesis, including increased zinc protoporphyrin levels, decreased hemoglobin levels, and microcytosis. Moreover, the TfN-bl/N-bl mice demonstrated the anticipated effect of iron restriction on red cell production (ie, no increase in red blood cell [RBC] count despite elevated erythropoietin levels), along with a poor response to exogenous erythropoietin. In contrast, the TfC-bl/C-bl mice had elevated RBC counts and an exaggerated response to exogenous erythropoietin sufficient to ameliorate the anemia. Observations in heterozygous mice further support a role for relative N vs C lobe iron occupancy in transferrin-mediated regulation of iron homeostasis and erythropoiesis.
- Published
- 2019
- Full Text
- View/download PDF
17. Lobe specificity of iron binding to transferrin modulates murine erythropoiesis and iron homeostasis
- Author
-
Parrow, Nermi L., Li, Yihang, Feola, Maria, Guerra, Amaliris, Casu, Carla, Prasad, Princy, Mammen, Luke, Ali, Faris, Vaicikauskas, Edvinas, Rivella, Stefano, Ginzburg, Yelena Z., and Fleming, Robert E.
- Abstract
Transferrin, the major plasma iron-binding molecule, interacts with cell-surface receptors to deliver iron, modulates hepcidin expression, and regulates erythropoiesis. Transferrin binds and releases iron via either or both of 2 homologous lobes (N and C). To test the hypothesis that the specificity of iron occupancy in the N vs C lobe influences transferrin function, we generated mice with mutations to abrogate iron binding in either lobe (TfN-blor TfC-bl). Mice homozygous for either mutation had hepatocellular iron loading and decreased liver hepcidin expression (relative to iron concentration), although to different magnitudes. Both mouse models demonstrated some aspects of iron-restricted erythropoiesis, including increased zinc protoporphyrin levels, decreased hemoglobin levels, and microcytosis. Moreover, the TfN-bl/N-blmice demonstrated the anticipated effect of iron restriction on red cell production (ie, no increase in red blood cell [RBC] count despite elevated erythropoietin levels), along with a poor response to exogenous erythropoietin. In contrast, the TfC-bl/C-blmice had elevated RBC counts and an exaggerated response to exogenous erythropoietin sufficient to ameliorate the anemia. Observations in heterozygous mice further support a role for relative N vs C lobe iron occupancy in transferrin-mediated regulation of iron homeostasis and erythropoiesis.
- Published
- 2019
- Full Text
- View/download PDF
18. Phenotypic HSPC Rescue By RNA Lipid Nanoparticles in a Murine Model of Fanconi Anemia
- Author
-
Omer, Linah, Banda, Omar, Adams, Sarah, Jung, Seul K, Rivella, Stefano, Alameh, Mohamad-Gabriel, Weissman, Drew, and Kurre, Peter
- Abstract
Background:Fanconi Anemia (FA) is a recessively heritable multisystem disorder that manifests with bone marrow failure in early childhood. Current gene therapy trials for FA rely on transplantation of ex vivotransduced autologous hematopoietic stem cells (HSCs). This approach is limited by poor mobilization efficiency and a depleted HSC pool in FA patients. The recent use of mRNA encapsulated within lipid nanoparticles (LNP mRNA) for cancer immunotherapy and vaccines has created an interest in adapting mRNA delivery for protein replacement therapies. Phase 1/2 trials have demonstrated both safety and efficacy for in vivotreatment of multiple monogenic metabolic disorders. We hypothesized that LNP Fancccould be developed as an in vivoprotein replacement therapy for FA.
- Published
- 2023
- Full Text
- View/download PDF
19. Differential Effect of Transferrin Lobe Iron Occupancy on a Murine Model of Inflammation
- Author
-
Parrow, Nermi L., George, Nisha Ajit, Ali, Faris, Wattad, Nadia, Guerra, Amaliris, Ginzburg, Yelena, Rivella, Stefano, and Fleming, Robert E.
- Abstract
Introduction: Iron status is both affected by and a determinant of the inflammatory response. Several lines of evidence support a role for transferrin as a signaling as well as an iron delivery molecule. We previously demonstrated that mice with transferrin mutations that prevent iron binding to the C-lobe of transferrin (C-blocked) have increased red cell production relative to erythropoietin and increased hepcidin expression relative to iron status compared to mice with transferrin mutations that prevent iron binding to the N-lobe of transferrin (N-blocked). Based on these observations, we hypothesize that two forms of transferrin would differentially modulate the hematopoietic and iron distribution changes that occur with inflammation. We explored this hypothesis by comparing the effects of lipopolysaccharide (LPS) administered either acutely or in repeated doses to wild-type, N-lobe blocked, or C-lobe blocked transferrin mutant mice.
- Published
- 2023
- Full Text
- View/download PDF
20. Differential Effects of Monoferric Transferrin Forms on Erythropoiesis Are Mediated By TFR2
- Author
-
Guerra, Amaliris, Rivera, Ariel, Hamilton, Nolan, An, Xiuli, Parrow, Nermi L., Ginzburg, Yelena, Fleming, Robert E., and Rivella, Stefano
- Abstract
Transferrin (TF) is a bilobed 80kD glycoprotein with N- and C-lobe iron binding sites. TF circulates as four forms: unbound to iron (apo-TF), monoferric iron bound to the N-lobe or C-lobe (mono-TF) or to both lobes (holo-TF). All TF forms interact with TF receptor-1 (TFR1), which is ubiquitously expressed and serves as the main mechanism for cellular iron delivery. TF also interacts with TFR2 which is mainly expressed by hepatocytes and erythroid precursors to modulate cellular signaling events regulating hepcidin expression and erythropoiesis. We previously generated N-lobe blocked ( Tf N-bl) or C-lobe blocked ( Tf C-bl) TF mutant mice, and observed marked differences between them in iron parameters, RBC count and EPO sensitivity (Parrow et al., 2019). In this current work, we investigate the effects of the mutated TFs on ineffective erythropoiesis in murine β-thalassemia intermedia. We moreover examine the consequences of erythroid knockout of TFR2 in the TF N-blocked and C-blocked mice.
- Published
- 2023
- Full Text
- View/download PDF
21. What can we learn from ineffective erythropoiesis in thalassemia?
- Author
-
Oikonomidou, Paraskevi Rea and Rivella, Stefano
- Abstract
Erythropoiesis is a dynamic process regulated at multiple levels to balance proliferation, differentiation and survival of erythroid progenitors. Ineffective erythropoiesis is a key feature of various diseases, including β-thalassemia. The pathogenic mechanisms leading to ineffective erythropoiesis are complex and still not fully understood. Altered survival and decreased differentiation of erythroid progenitors are both critical processes contributing to reduced production of mature red blood cells. Recent studies have identified novel important players and provided major advances in the development of targeted therapeutic approaches. In this review, β-thalassemia is used as a paradigmatic example to describe our current knowledge on the mechanisms leading to ineffective erythropoiesis and novel treatments that may have the potential to improve the clinical phenotype of associated diseases in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
22. Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of ß-thalassemia
- Author
-
Guerra, Amaliris, Oikonomidou, Paraskevi Rea, Sinha, Sayantani, Zhang, Jianbing, Lo Presti, Vania, Hamilton, Callum R., Breda, Laura, Casu, Carla, La, Ping, Martins, Ana C., Sendamarai, Anoop K., Fleming, Mark, and Rivella, Stefano
- Published
- 2019
- Full Text
- View/download PDF
23. Lack of Gdf11does not improve anemia or prevent the activity of RAP-536 in a mouse model of β-thalassemia
- Author
-
Guerra, Amaliris, Oikonomidou, Paraskevi Rea, Sinha, Sayantani, Zhang, Jianbing, Lo Presti, Vania, Hamilton, Callum R., Breda, Laura, Casu, Carla, La, Ping, Martins, Ana C., Sendamarai, Anoop K., Fleming, Mark, and Rivella, Stefano
- Published
- 2019
- Full Text
- View/download PDF
24. Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia
- Author
-
Rivella, Stefano
- Abstract
β-Thalassemia (BT) is an inherited genetic disorder that is characterized by ineffective erythropoiesis (IE), leading to anemia and abnormal iron metabolism. IE is an abnormal expansion of the number of erythroid progenitor cells with unproductive synthesis of enucleated erythrocytes, leading to anemia and hypoxia. Anemic patients affected by BT suffer from iron overload, even in the absence of chronic blood transfusion, suggesting the presence of ≥1 erythroid factor with the ability to modulate iron metabolism and dietary iron absorption. Recent studies suggest that decreased erythroid cell differentiation and survival also contribute to IE, aggravating the anemia in BT. Furthermore, hypoxia can also affect and increase iron absorption. Understanding the relationship between iron metabolism and IE could provide important insights into the BT condition and help to develop novel treatments. In fact, genetic or pharmacological manipulations of iron metabolism or erythroid cell differentiation and survival have been shown to improve IE, iron overload, and anemia in animal models of BT. Based on those findings, new therapeutic approaches and drugs have been proposed; clinical trials are underway that have the potential to improve erythrocyte production, as well as to reduce the iron overload and organ toxicity in BT and in other disorders characterized by IE.
- Published
- 2019
- Full Text
- View/download PDF
25. Iron metabolism under conditions of ineffective erythropoiesis in β-thalassemia
- Author
-
Rivella, Stefano
- Abstract
β-Thalassemia (BT) is an inherited genetic disorder that is characterized by ineffective erythropoiesis (IE), leading to anemia and abnormal iron metabolism. IE is an abnormal expansion of the number of erythroid progenitor cells with unproductive synthesis of enucleated erythrocytes, leading to anemia and hypoxia. Anemic patients affected by BT suffer from iron overload, even in the absence of chronic blood transfusion, suggesting the presence of ≥1 erythroid factor with the ability to modulate iron metabolism and dietary iron absorption. Recent studies suggest that decreased erythroid cell differentiation and survival also contribute to IE, aggravating the anemia in BT. Furthermore, hypoxia can also affect and increase iron absorption. Understanding the relationship between iron metabolism and IE could provide important insights into the BT condition and help to develop novel treatments. In fact, genetic or pharmacological manipulations of iron metabolism or erythroid cell differentiation and survival have been shown to improve IE, iron overload, and anemia in animal models of BT. Based on those findings, new therapeutic approaches and drugs have been proposed; clinical trials are underway that have the potential to improve erythrocyte production, as well as to reduce the iron overload and organ toxicity in BT and in other disorders characterized by IE.
- Published
- 2019
- Full Text
- View/download PDF
26. In Vivo Modification of Hematopoietic Stem Cells By Targeted Lipid Nanoparticles Encapsulating mRNA
- Author
-
Breda, Laura, Papp, Tyler E, Triebwasser, Michael, Yadegari, Amir, Fedorky, Megan T, Tanaka, Naoto, Ni, Houping, Weissman, Drew, Rivella, Stefano, and Parhiz, Hamideh
- Published
- 2022
- Full Text
- View/download PDF
27. TNFα and Anti-IFNγ Rescues Chronic Anemia of Inflammation Phenotype in Tnfαko Mice Treated with Heat-Killed Brucella Abortus
- Author
-
Guerra, Amaliris, Lo Presti, Vania, Chen, Ding-Wen, Martins, Ana Catarina, Castruccio Castracani, Carlo, Gupta, Ritama, Bennett, Laura, Gozzelino, Raffaella, Paulson, Robert, Kurre, Peter, Rivella, Stefano, and Casu, Carla
- Published
- 2022
- Full Text
- View/download PDF
28. Combination of a TGF-β Ligand Trap (RAP-GRL) and TMPRSS6-ASO Is Superior for Correcting β-Thalassemia
- Author
-
Guerra, Amaliris, Demsko, Perry, Rivera, Ariel, Castruccio Castracani, Carlo, Breda, Laura, Tanaka, Naoto, Guo, Shuling, and Rivella, Stefano
- Published
- 2022
- Full Text
- View/download PDF
29. Differential Effects of Monoferric Forms of Transferrin on Mouse Models of Anemia of Inflammation and Congenital Anemia
- Author
-
Guerra, Amaliris, Martins, Ana Catarina, Rivera, Ariel, Parrow, Nermi, Gozzelino, Raffaella, Ginzburg, Yelena, Fleming, Robert E, and Rivella, Stefano
- Published
- 2022
- Full Text
- View/download PDF
30. In Vivo Modification of Hematopoietic Stem Cells By Targeted Lipid Nanoparticles Encapsulating mRNA
- Author
-
Breda, Laura, Papp, Tyler E, Triebwasser, Michael, Yadegari, Amir, Fedorky, Megan T, Tanaka, Naoto, Ni, Houping, Weissman, Drew, Rivella, Stefano, and Parhiz, Hamideh
- Published
- 2022
- Full Text
- View/download PDF
31. Direct Delivery of mRNA-Loaded Lipid Nanoparticles to the Hematopoietic Stem Cell Niche
- Author
-
Banda, Omar, Alameh, Mohamad-Gabriel, Jung, Seul, Weissman, Drew, Rivella, Stefano, and Kurre, Peter
- Published
- 2022
- Full Text
- View/download PDF
32. Differential Effects of Monoferric Forms of Transferrin on Mouse Models of Anemia of Inflammation and Congenital Anemia
- Author
-
Guerra, Amaliris, Martins, Ana Catarina, Rivera, Ariel, Parrow, Nermi, Gozzelino, Raffaella, Ginzburg, Yelena, Fleming, Robert E, and Rivella, Stefano
- Published
- 2022
- Full Text
- View/download PDF
33. The Effect of Monoferric Transferrins on Hypoferremia in a Murine Model of Inflammation
- Author
-
Parrow, Nermi, George, Nisha, Ali, Faris, Wattad, Nadia, Guerra, Amaliris, Ginzburg, Yelena, Rivella, Stefano, and Fleming, Robert E
- Published
- 2022
- Full Text
- View/download PDF
34. The Effect of Monoferric Transferrins on Hypoferremia in a Murine Model of Inflammation
- Author
-
Parrow, Nermi, George, Nisha, Ali, Faris, Wattad, Nadia, Guerra, Amaliris, Ginzburg, Yelena, Rivella, Stefano, and Fleming, Robert E
- Published
- 2022
- Full Text
- View/download PDF
35. TNFα and Anti-IFNγ Rescues Chronic Anemia of Inflammation Phenotype in Tnfαko Mice Treated with Heat-Killed Brucella Abortus
- Author
-
Guerra, Amaliris, Lo Presti, Vania, Chen, Ding-Wen, Martins, Ana Catarina, Castruccio Castracani, Carlo, Gupta, Ritama, Bennett, Laura, Gozzelino, Raffaella, Paulson, Robert, Kurre, Peter, Rivella, Stefano, and Casu, Carla
- Published
- 2022
- Full Text
- View/download PDF
36. Direct Delivery of mRNA-Loaded Lipid Nanoparticles to the Hematopoietic Stem Cell Niche
- Author
-
Banda, Omar, Alameh, Mohamad-Gabriel, Jung, Seul, Weissman, Drew, Rivella, Stefano, and Kurre, Peter
- Published
- 2022
- Full Text
- View/download PDF
37. Combination of a TGF-β Ligand Trap (RAP-GRL) and TMPRSS6-ASO Is Superior for Correcting β-Thalassemia
- Author
-
Guerra, Amaliris, Demsko, Perry, Rivera, Ariel, Castruccio Castracani, Carlo, Breda, Laura, Tanaka, Naoto, Guo, Shuling, and Rivella, Stefano
- Published
- 2022
- Full Text
- View/download PDF
38. Hepcidin agonists as therapeutic tools
- Author
-
Casu, Carla, Nemeth, Elizabeta, and Rivella, Stefano
- Abstract
Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.
- Published
- 2018
- Full Text
- View/download PDF
39. Hepcidin agonists as therapeutic tools
- Author
-
Casu, Carla, Nemeth, Elizabeta, and Rivella, Stefano
- Abstract
Hepcidin agonists are a new class of compounds that regulate blood iron levels, limit iron absorption, and could improve the treatment of hemochromatosis, β-thalassemia, polycythemia vera, and other disorders in which disrupted iron homeostasis causes or contributes to disease. Hepcidin agonists also have the potential to prevent severe complications of siderophilic infections in patients with iron overload or chronic liver disease. This review highlights the preclinical studies that support the development of hepcidin agonists for the treatment of these disorders.
- Published
- 2018
- Full Text
- View/download PDF
40. Ineffective Erythropoiesis: Anemia and Iron Overload
- Author
-
Gupta, Ritama, Musallam, Khaled M., Taher, Ali T., and Rivella, Stefano
- Abstract
Stress erythropoiesis (SE) is characterized by an imbalance in erythroid proliferation and differentiation under increased demands of erythrocyte generation and tissue oxygenation. β-thalassemia represents a chronic state of SE, called ineffective erythropoiesis (IE), exhibiting an expansion of erythroid-progenitor pool and deposition of alpha chains on erythrocyte membranes, causing cell death and anemia. Concurrently, there is a decrease in hepcidin expression and a subsequent state of iron overload. There are substantial investigative efforts to target increased iron absorption under IE. There are also avenues for targeting cell contact and signaling within erythroblastic islands under SE, for therapeutic benefits.
- Published
- 2018
- Full Text
- View/download PDF
41. Emerging Therapies
- Author
-
Guerra, Amaliris, Musallam, Khaled M., Taher, Ali T., and Rivella, Stefano
- Abstract
At present, the only definitive cure for β-thalassemia is a bone marrow transplant (BMT); however, HLA–blood-matched donors are scarcely available. Current therapies undergoing clinical investigation with most potential for therapeutic benefit are the β-globin gene transfer of patient-specific hematopoietic stem cells followed by autologous BMT. Other emerging therapies deliver exogenous regulators of several key modulators of erythropoiesis or iron homeostasis. This review focuses on current approaches for the treatment of hemoglobinopathies caused by disruptions of β-globin.
- Published
- 2018
- Full Text
- View/download PDF
42. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin
- Author
-
Aschemeyer, Sharraya, Qiao, Bo, Stefanova, Deborah, Valore, Erika V., Sek, Albert C., Ruwe, T. Alex, Vieth, Kyle R., Jung, Grace, Casu, Carla, Rivella, Stefano, Jormakka, Mika, Mackenzie, Bryan, Ganz, Tomas, and Nemeth, Elizabeta
- Abstract
Nonclassical ferroportin disease (FD) is a form of hereditary hemochromatosis caused by mutations in the iron transporter ferroportin (Fpn), resulting in parenchymal iron overload. Fpn is regulated by the hormone hepcidin, which induces Fpn endocytosis and cellular iron retention. We characterized 11 clinically relevant and 5 nonclinical Fpn mutations using stably transfected, inducible isogenic cell lines. All clinical mutants were functionally resistant to hepcidin as a consequence of either impaired hepcidin binding or impaired hepcidin-dependent ubiquitination despite intact hepcidin binding. Mapping the residues onto 2 computational models of the human Fpn structure indicated that (1) mutations that caused ubiquitination-resistance were positioned at helix-helix interfaces, likely preventing the hepcidin-induced conformational change, (2) hepcidin binding occurred within the central cavity of Fpn, (3) hepcidin interacted with up to 4 helices, and (4) hepcidin binding should occlude Fpn and interfere with iron export independently of endocytosis. We experimentally confirmed hepcidin-mediated occlusion of Fpn in the absence of endocytosis in multiple cellular systems: HEK293 cells expressing an endocytosis-defective Fpn mutant (K8R), Xenopus oocytes expressing wild-type or K8R Fpn, and mature human red blood cells. We conclude that nonclassical FD is caused by Fpn mutations that decrease hepcidin binding or hinder conformational changes required for ubiquitination and endocytosis of Fpn. The newly documented ability of hepcidin and its agonists to occlude iron transport may facilitate the development of broadly effective treatments for hereditary iron overload disorders.
- Published
- 2018
- Full Text
- View/download PDF
43. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin
- Author
-
Aschemeyer, Sharraya, Qiao, Bo, Stefanova, Deborah, Valore, Erika V., Sek, Albert C., Ruwe, T. Alex, Vieth, Kyle R., Jung, Grace, Casu, Carla, Rivella, Stefano, Jormakka, Mika, Mackenzie, Bryan, Ganz, Tomas, and Nemeth, Elizabeta
- Abstract
Nonclassical ferroportin disease (FD) is a form of hereditary hemochromatosis caused by mutations in the iron transporter ferroportin (Fpn), resulting in parenchymal iron overload. Fpn is regulated by the hormone hepcidin, which induces Fpn endocytosis and cellular iron retention. We characterized 11 clinically relevant and 5 nonclinical Fpn mutations using stably transfected, inducible isogenic cell lines. All clinical mutants were functionally resistant to hepcidin as a consequence of either impaired hepcidin binding or impaired hepcidin-dependent ubiquitination despite intact hepcidin binding. Mapping the residues onto 2 computational models of the human Fpn structure indicated that (1) mutations that caused ubiquitination-resistance were positioned at helix-helix interfaces, likely preventing the hepcidin-induced conformational change, (2) hepcidin binding occurred within the central cavity of Fpn, (3) hepcidin interacted with up to 4 helices, and (4) hepcidin binding should occlude Fpn and interfere with iron export independently of endocytosis. We experimentally confirmed hepcidin-mediated occlusion of Fpn in the absence of endocytosis in multiple cellular systems: HEK293 cells expressing an endocytosis-defective Fpn mutant (K8R), Xenopusoocytes expressing wild-type or K8R Fpn, and mature human red blood cells. We conclude that nonclassical FD is caused by Fpn mutations that decrease hepcidin binding or hinder conformational changes required for ubiquitination and endocytosis of Fpn. The newly documented ability of hepcidin and its agonists to occlude iron transport may facilitate the development of broadly effective treatments for hereditary iron overload disorders.
- Published
- 2018
- Full Text
- View/download PDF
44. Tropomodulin 1 controls erythroblast enucleation via regulation of F-actin in the enucleosome
- Author
-
Nowak, Roberta B., Papoin, Julien, Gokhin, David S., Casu, Carla, Rivella, Stefano, Lipton, Jeffrey M., Blanc, Lionel, and Fowler, Velia M.
- Abstract
Biogenesis of mammalian red blood cells requires nuclear expulsion by orthochromatic erythoblasts late in terminal differentiation (enucleation), but the mechanism is largely unexplained. Here, we employed high-resolution confocal microscopy to analyze nuclear morphology and F-actin rearrangements during the initiation, progression, and completion of mouse and human erythroblast enucleation in vivo. Mouse erythroblast nuclei acquire a dumbbell-shaped morphology during enucleation, whereas human bone marrow erythroblast nuclei unexpectedly retain their spherical morphology. These morphological differences are linked to differential expression of Lamin isoforms, with primary mouse erythroblasts expressing only Lamin B and primary human erythroblasts only Lamin A/C. We did not consistently identify a continuous F-actin ring at the cell surface constriction in mouse erythroblasts, nor at the membrane protein-sorting boundary in human erythroblasts, which do not have a constriction, arguing against a contractile ring-based nuclear expulsion mechanism. However, both mouse and human erythroblasts contain an F-actin structure at the rear of the translocating nucleus, enriched in tropomodulin 1 (Tmod1) and nonmuscle myosin IIB. We investigated Tmod1 function in mouse and human erythroblasts both in vivo and in vitro and found that absence of Tmod1 leads to enucleation defects in mouse fetal liver erythroblasts, and in CD34+hematopoietic stem and progenitor cells, with increased F-actin in the structure at the rear of the nucleus. This novel structure, the “enucleosome,” may mediate common cytoskeletal mechanisms underlying erythroblast enucleation, notwithstanding the morphological heterogeneity of enucleation across species.
- Published
- 2017
- Full Text
- View/download PDF
45. Tropomodulin 1 controls erythroblast enucleation via regulation of F-actin in the enucleosome
- Author
-
Nowak, Roberta B., Papoin, Julien, Gokhin, David S., Casu, Carla, Rivella, Stefano, Lipton, Jeffrey M., Blanc, Lionel, and Fowler, Velia M.
- Abstract
Biogenesis of mammalian red blood cells requires nuclear expulsion by orthochromatic erythoblasts late in terminal differentiation (enucleation), but the mechanism is largely unexplained. Here, we employed high-resolution confocal microscopy to analyze nuclear morphology and F-actin rearrangements during the initiation, progression, and completion of mouse and human erythroblast enucleation in vivo. Mouse erythroblast nuclei acquire a dumbbell-shaped morphology during enucleation, whereas human bone marrow erythroblast nuclei unexpectedly retain their spherical morphology. These morphological differences are linked to differential expression of Lamin isoforms, with primary mouse erythroblasts expressing only Lamin B and primary human erythroblasts only Lamin A/C. We did not consistently identify a continuous F-actin ring at the cell surface constriction in mouse erythroblasts, nor at the membrane protein-sorting boundary in human erythroblasts, which do not have a constriction, arguing against a contractile ring-based nuclear expulsion mechanism. However, both mouse and human erythroblasts contain an F-actin structure at the rear of the translocating nucleus, enriched in tropomodulin 1 (Tmod1) and nonmuscle myosin IIB. We investigated Tmod1 function in mouse and human erythroblasts both in vivo and in vitro and found that absence of Tmod1 leads to enucleation defects in mouse fetal liver erythroblasts, and in CD34+ hematopoietic stem and progenitor cells, with increased F-actin in the structure at the rear of the nucleus. This novel structure, the “enucleosome,” may mediate common cytoskeletal mechanisms underlying erythroblast enucleation, notwithstanding the morphological heterogeneity of enucleation across species.
- Published
- 2017
- Full Text
- View/download PDF
46. Targeting iron metabolism in drug discovery and delivery
- Author
-
Crielaard, Bart J., Lammers, Twan, and Rivella, Stefano
- Abstract
Iron fulfils a central role in many essential biochemical processes in human physiology; thus, proper processing of iron is crucial. Although iron metabolism is subject to relatively strict physiological control, numerous disorders, such as cancer and neurodegenerative diseases, have recently been linked to deregulated iron homeostasis. Consequently, iron metabolism constitutes a promising and largely unexploited therapeutic target for the development of new pharmacological treatments for these diseases. Several iron metabolism-targeted therapies are already under clinical evaluation for haematological disorders, and these and newly developed therapeutic agents are likely to have substantial benefit in the clinical management of iron metabolism-associated diseases, for which few efficacious treatments are currently available.
- Published
- 2017
- Full Text
- View/download PDF
47. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice
- Author
-
Li, Huihui, Choesang, Tenzin, Bao, Weili, Chen, Huiyong, Feola, Maria, Garcia-Santos, Daniel, Li, Jie, Sun, Shuming, Follenzi, Antonia, Pham, Petra, Liu, Jing, Zhang, Jinghua, Ponka, Prem, An, Xiuli, Mohandas, Narla, Fleming, Robert E., Rivella, Stefano, Li, Guiyuan, and Ginzburg, Yelena Z.
- Abstract
Iron availability for erythropoiesis and its dysregulation in β-thalassemia are incompletely understood. We previously demonstrated that exogenous apotransferrin leads to more effective erythropoiesis, decreasing erythroferrone (ERFE) and derepressing hepcidin in β-thalassemic mice. Transferrin-bound iron binding to transferrin receptor 1 (TfR1) is essential for cellular iron delivery during erythropoiesis. We hypothesize that apotransferrin's effect is mediated via decreased TfR1 expression and evaluate TfR1 expression in β-thalassemic mice in vivo and in vitro with and without added apotransferrin. Our findings demonstrate that β-thalassemic erythroid precursors overexpress TfR1, an effect that can be reversed by the administration of exogenous apotransferrin. In vitro experiments demonstrate that apotransferrin inhibits TfR1 expression independent of erythropoietin- and iron-related signaling, decreases TfR1 partitioning to reticulocytes during enucleation, and enhances enucleation of defective β-thalassemic erythroid precursors. These findings strongly suggest that overexpressed TfR1 may play a regulatory role contributing to iron overload and anemia in β-thalassemic mice. To evaluate further, we crossed TfR1+/−mice, themselves exhibiting iron-restricted erythropoiesis with increased hepcidin, with β-thalassemic mice. Resultant double-heterozygote mice demonstrate long-term improvement in ineffective erythropoiesis, hepcidin derepression, and increased erythroid enucleation in relation to β-thalassemic mice. Our data demonstrate for the first time that TfR1+/−haploinsufficiency reverses iron overload specifically in β-thalassemic erythroid precursors. Taken together, decreasing TfR1 expression during β-thalassemic erythropoiesis, either directly via induced haploinsufficiency or via exogenous apotransferrin, decreases ineffective erythropoiesis and provides an endogenous mechanism to upregulate hepcidin, leading to sustained iron-restricted erythropoiesis and preventing systemic iron overload in β-thalassemic mice.
- Published
- 2017
- Full Text
- View/download PDF
48. Decreasing TfR1 expression reverses anemia and hepcidin suppression in β-thalassemic mice
- Author
-
Li, Huihui, Choesang, Tenzin, Bao, Weili, Chen, Huiyong, Feola, Maria, Garcia-Santos, Daniel, Li, Jie, Sun, Shuming, Follenzi, Antonia, Pham, Petra, Liu, Jing, Zhang, Jinghua, Ponka, Prem, An, Xiuli, Mohandas, Narla, Fleming, Robert E., Rivella, Stefano, Li, Guiyuan, and Ginzburg, Yelena Z.
- Abstract
Iron availability for erythropoiesis and its dysregulation in β-thalassemia are incompletely understood. We previously demonstrated that exogenous apotransferrin leads to more effective erythropoiesis, decreasing erythroferrone (ERFE) and derepressing hepcidin in β-thalassemic mice. Transferrin-bound iron binding to transferrin receptor 1 (TfR1) is essential for cellular iron delivery during erythropoiesis. We hypothesize that apotransferrin’s effect is mediated via decreased TfR1 expression and evaluate TfR1 expression in β-thalassemic mice in vivo and in vitro with and without added apotransferrin. Our findings demonstrate that β-thalassemic erythroid precursors overexpress TfR1, an effect that can be reversed by the administration of exogenous apotransferrin. In vitro experiments demonstrate that apotransferrin inhibits TfR1 expression independent of erythropoietin- and iron-related signaling, decreases TfR1 partitioning to reticulocytes during enucleation, and enhances enucleation of defective β-thalassemic erythroid precursors. These findings strongly suggest that overexpressed TfR1 may play a regulatory role contributing to iron overload and anemia in β-thalassemic mice. To evaluate further, we crossed TfR1+/− mice, themselves exhibiting iron-restricted erythropoiesis with increased hepcidin, with β-thalassemic mice. Resultant double-heterozygote mice demonstrate long-term improvement in ineffective erythropoiesis, hepcidin derepression, and increased erythroid enucleation in relation to β-thalassemic mice. Our data demonstrate for the first time that TfR1+/− haploinsufficiency reverses iron overload specifically in β-thalassemic erythroid precursors. Taken together, decreasing TfR1 expression during β-thalassemic erythropoiesis, either directly via induced haploinsufficiency or via exogenous apotransferrin, decreases ineffective erythropoiesis and provides an endogenous mechanism to upregulate hepcidin, leading to sustained iron-restricted erythropoiesis and preventing systemic iron overload in β-thalassemic mice.
- Published
- 2017
- Full Text
- View/download PDF
49. Lack of hepcidin ameliorates anemia and improves growth in an adenine-induced mouse model of chronic kidney disease
- Author
-
Akchurin, Oleh, Sureshbabu, Angara, Doty, Steve B., Zhu, Yuan-Shan, Patino, Edwin, Cunningham-Rundles, Susanna, Choi, Mary E., Boskey, Adele, and Rivella, Stefano
- Abstract
Growth delay is common in children with chronic kidney disease (CKD), often associated with poor quality of life. The role of anemia in uremic growth delay is poorly understood. Here we describe an induction of uremic growth retardation by a 0.2% adenine diet in wild-type (WT) and hepcidin gene (Hamp) knockout (KO) mice, compared with their respective littermates fed a regular diet. Experiments were started at weaning (3 wk). After 8 wk, blood was collected and mice were euthanized. Adenine-fed WT mice developed CKD (blood urea nitrogen 82.8 ± 11.6 mg/dl and creatinine 0.57 ± 0.07 mg/dl) and were 2.1 cm shorter compared with WT controls. WT adenine-fed mice were anemic and had low serum iron, elevated Hamp, and elevated IL6 and TNF-α. WT adenine-fed mice had advanced mineral bone disease (serum phosphorus 16.9 ± 3.1 mg/dl and FGF23 204.0 ± 115.0 ng/ml) with loss of cortical and trabecular bone volume seen on microcomputed tomography. Hampdisruption rescued the anemia phenotype resulting in improved growth rate in mice with CKD, thus providing direct experimental evidence of the relationship between Hamp pathway and growth impairment in CKD. Hampdisruption ameliorated CKD-induced growth hormone-insulin-like growth factor 1 axis derangements and growth plate alterations. Disruption of Hampdid not mitigate the development of uremia, inflammation, and mineral and bone disease in this model. Taken together, these results indicate that an adenine diet can be successfully used to study growth in mice with CKD. Hepcidin appears to be related to pathways of growth retardation in CKD suggesting that investigation of hepcidin-lowering therapies in juvenile CKD is warranted.
- Published
- 2016
- Full Text
- View/download PDF
50. Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers
- Author
-
Breda, Laura, Motta, Irene, Lourenco, Silvia, Gemmo, Chiara, Deng, Wulan, Rupon, Jeremy W., Abdulmalik, Osheiza Y., Manwani, Deepa, Blobel, Gerd A., and Rivella, Stefano
- Abstract
Overcoming the silencing of the fetal γ-globin gene has been a long-standing goal in the treatment of sickle cell disease (SCD). The major transcriptional enhancer of the β-globin locus, called the locus control region (LCR), dynamically interacts with the developmental stage-appropriate β-type globin genes via chromatin looping, a process requiring the protein Ldb1. In adult erythroid cells, the LCR can be redirected from the adult β- to the fetal γ-globin promoter by tethering Ldb1 to the human γ-globin promoter with custom-designed zinc finger (ZF) proteins (ZF-Ldb1), leading to reactivation of γ-globin gene expression. To compare this approach to pharmacologic reactivation of fetal hemoglobin (HbF), hematopoietic cells from patients with SCD were treated with a lentivirus expressing the ZF-Ldb1 or with chemical HbF inducers. The HbF increase in cells treated with ZF-Ldb1 was more than double that observed with decitabine and pomalidomide; butyrate had an intermediate effect whereas tranylcypromine and hydroxyurea showed relatively low HbF reactivation. ZF-Ldb1 showed comparatively little toxicity, and reduced sickle hemoglobin (HbS) synthesis as well as sickling of SCD erythroid cells under hypoxic conditions. The efficacy and low cytotoxicity of lentiviral-mediated ZF-Ldb1 gene transfer compared with the drug regimens support its therapeutic potential for the treatment of SCD.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.